Lazard Asset Management
BMRN icon

Lazard Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lazard Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$2.97M – 1897
2025
Q4 		$2.97M Buy
+50,000
New +$2.72M 0.01% 719

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's BMRN Position: Q1 2026 in Review

Lazard Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 13% in Q1 2026, buying an estimated $2.22M and bringing the position to 325,851 shares worth $18.4M. The position accounts for 0.03% of the portfolio, ranked #338.

Lazard Asset Management first reported a position in BMRN in Q2 2014 and has held it in 34 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Lazard Asset Management held 325,851 shares of BioMarin Pharmaceuticals worth $18.4M as of Q1 2026.
  • Lazard Asset Management bought 38,138 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.22M.
  • BioMarin Pharmaceuticals made up 0.03% of Lazard Asset Management's portfolio in Q1 2026, its #338 holding.
  • Lazard Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 34 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.